{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-269959","form_type":"8-K","ticker":"RVTY","cik":"0000031791","company_name":"REVVITY, INC.","filed_at":"2021-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.326690+00:00","generated_at":"2026-06-29T04:39:18.522940+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PerkinElmer issues $2.3B in senior notes to finance BioLegend acquisition","bullets":["Issued $2.3B aggregate: $500M 0.55% notes due 2023, $800M 0.85% due 2024, $500M 1.90% due 2028, $500M 2.25% due 2031.","Net proceeds ~$2.28B to partially fund $5.7B BioLegend acquisition announced July 25, 2021.","Special mandatory redemption at 101% if BioLegend deal not closed by Jan 31, 2022.","Bridge loan commitments reduced to $514M after net proceeds.","Notes are general unsecured, rank equally with other unsecured debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-269959","json":"https://secwatch.observer/filing/0001193125-21-269959.json","markdown":"https://secwatch.observer/filing/0001193125-21-269959.md","text":"https://secwatch.observer/filing/0001193125-21-269959.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/31791/000119312521269959/0001193125-21-269959-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/31791/000119312521269959/d204305d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T04:39:18.522940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}